Custom Criteria for
BlueCross Blue Shield of Rhode Island Commercial

XGEVA (denosumab)

GPI CODING:

30044530002030

DESCRIPTION:

Xgeva is a RANK ligand (RANKL) inhibitor indicated for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. Xgeva is not indicated for the prevention of SREs in patients with multiple myeloma.

APPROVAL DURATION:

Approval duration: 1 year

CRITERIA FOR XGEVA

I. Patient has documented bone metastases from a solid tumor cancer **AND**
II. Patient does not have multiple myeloma **AND**
III. Patient does not have pre-existing hypocalcemia **OR**
IV. Patient will have hypocalcemia corrected prior to starting Xgeva **AND**
V. Patient will receive calcium and vitamin D as needed to prevent hypocalcemia